Demographic, immunologic, and virologic characteristics of patients, according to therapy group
| Characteristic . | Type of therapy . | ||
|---|---|---|---|
| ART/RS (n = 20) . | ART (n = 15) . | ART + IL-2 (n = 49) . | |
| Risk factor | |||
| Heterosexual | 9 | 2 | 14 |
| Homosexual | 11 | 8 | 19 |
| IVDU | 0 | 5 | 16 |
| Sex | |||
| Male | 13 | 10 | 30 |
| Female | 7 | 5 | 19 |
| Mean age, y (range) | 38.6 (27-56) | 40.7 (35-52) | 39.1 (27-64) |
| Mean time since therapy began, mo (range) | 57.4 (25-69) | 55.4 (49-61) | 53.3 (49-61) |
| Mean CD4+cells/μL (range) | 667 (303-1 200) | 348 (201-490) | 353.5 (127-684) |
| Mean CD8+ cells/μL (range) | 1 053 (454-2 138) | 1 001 (470-2 490) | 763 (221-1 900) |
| Mean HIV-1 plasma load (genome equivalent/mL)* | 50 643 (500-325 000) | 3 392 (500-14 700) | 5 746 (500-39 810) |
| No. with plasma positive for HHV-8 | 0 | 0 | 2 |
| No. with PBMCs positive for HHV-8 | 0 | 0 | 4 |
| No. with anti–HHV-8 lytic/latent Abs (%) | 9 (45) | 5 (33) | 17 (37) |
| Characteristic . | Type of therapy . | ||
|---|---|---|---|
| ART/RS (n = 20) . | ART (n = 15) . | ART + IL-2 (n = 49) . | |
| Risk factor | |||
| Heterosexual | 9 | 2 | 14 |
| Homosexual | 11 | 8 | 19 |
| IVDU | 0 | 5 | 16 |
| Sex | |||
| Male | 13 | 10 | 30 |
| Female | 7 | 5 | 19 |
| Mean age, y (range) | 38.6 (27-56) | 40.7 (35-52) | 39.1 (27-64) |
| Mean time since therapy began, mo (range) | 57.4 (25-69) | 55.4 (49-61) | 53.3 (49-61) |
| Mean CD4+cells/μL (range) | 667 (303-1 200) | 348 (201-490) | 353.5 (127-684) |
| Mean CD8+ cells/μL (range) | 1 053 (454-2 138) | 1 001 (470-2 490) | 763 (221-1 900) |
| Mean HIV-1 plasma load (genome equivalent/mL)* | 50 643 (500-325 000) | 3 392 (500-14 700) | 5 746 (500-39 810) |
| No. with plasma positive for HHV-8 | 0 | 0 | 2 |
| No. with PBMCs positive for HHV-8 | 0 | 0 | 4 |
| No. with anti–HHV-8 lytic/latent Abs (%) | 9 (45) | 5 (33) | 17 (37) |
RS indicates patients with recent HIV seroconversion; and IVDU, intravenous drug user.
The lower limit of detection and quantification was 500 genome equivalents/mL.